Transitional cell carcinoma of the urinary bladder: A clinicopathological study

Singapore Medical Journal

Volumn 49, Issue 10, 2008, Pages 790-794

  Matalka, Ismail I ^a   Bani Hani, K ^b   Shotar, A ^a   Bani Hani, O ^b   Bani Hani, I ^b  

^a KING ABDULLAH UNIVERSITY HOSPITAL   (Jordan)

^b Department of Surgery ^*

Author keywords

Bladder cancer; Transitional cell carcinoma; Urinary bladder

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER MORTALITY; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; JORDAN; MAJOR CLINICAL STUDY; MALE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINARY DIVERSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; JORDAN; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 54949146069     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. Cancer J Clin 2007; 57:43-66.
2. Anton-Culver H, Lee-Feldstein A, Taylor TH. Occupation and bladder cancer risk. Am J Epidemiol 1992; 136:89-94.
3. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997; 13:291-8.
4. Kroft SH, Oyasu R. Urinary bladder cancer: mechanisms of development and progression. Lab Invest 1994; 71:158-74.
5. Pedersen-Bjergaard J, Ersboll J, Hansen VL, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988; 318:1028-32.
6. Gaertner RW, Theriault GP. Risk of bladder cancer in foundry workers: a meta-analysis. Occup Environ Med 2002; 59:655-63.
7. Metts MC, Metts JC, Milito SJ, Thomas CR Jr. Bladder cancer: a review of diagnosis and management. J Natl Med Assoc 2000; 92:285-94.
8. Loening S, Narayana A, Yoder L, et al. Factors influencing the recurrence rate of bladder cancer. J Urol 1980; 123:29-31.
9. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22:1435-48.
10. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumors. New York: John Wiley & Sons, 1997.
11. Al-Kayed S, Hijawi B. Cancer incidence in Jordan 1998 report. National Cancer Registry. The Hashemite Kingdom of Jordan. Amman (HKJ), Ministry of Health, 2000.
12. Shaaban AA, Orkubi SA, Said MT, Yousef B, Abomelha MS. Squamous cell carcinoma of the urinary bladder. Ann Saudi Med 1997; 17:115-9.
13. El Bolkainy MN, Mokhtar NM, Ghoneim MA, Hussein MH. The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer 1981; 48:2643-8.
14. Aghaji AE, Mbonu OO. Bladder tumors in Enugu, Nigeria. Br J Urol 1989; 64:399-402.
15. Elem B, Patil PS. Pattern of urological malignancy in Zambia: a hospital-based histopathological study. Br J Urol 1991; 67:37-9.
16. Wynder EL, Goldsmith R. The epidemiology of bladder cancer: a second look. Cancer 1977; 40:1246-68.
17. Messing EM, Vaillancourt A. Hematuria screening for bladder cancer. J Occup Med 1990; 32:838-45.
18. Messing EM, Young TB, Hunt VB, et al. Home screening for hematuria: results of a multiclinic study. J Urol 1992; 148:289-92.
19. de Vere White RW, Stapp E. Predicting prognosis in patients with superficial bladder cancer. Oncology 1998; 12:1717-23.
20. Abel PD. Prognostic indices in transitional cell carcinoma of the bladder. Br J Urol 1988; 62:103-9.
21. Pagano F, Bassi P, Galetti TP, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145:45-50.
22. Messing EM, Young TB, Hunt VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995; 45:387-96.
23. Kern WH. The grade and pathologic stage of bladder cancer. Cancer 1984; 53:1185-9.
24. Shaaban AA, Tribukait B, el-Bedeiwy A, Ghoneim MA. Prediction of lymph node metastasis in bladder carcinoma with deoxyribonucleic acid flow cytometry. J Urol 1990; 144:884-7.
25. Giannopoulos A, Manousakas T, Gounari A, et al. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 2001; 166:470-5.
26. Mian C, Lodde M, Haitel A, et al. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology 2000; 56:228-31.
27. Cassel A, Rahat MA, Lahat N, et al. Telomerase activity and cytokeratin 20 as markers for the detection and followup of transitional cell carcinoma: an unfulfilled promise. J Urol 2001; 166:841-4.
28. Topsakal M, Karadeniz T, Anac M, Donmezer S, Besisik A. Assessment of fibrin-fibrinogen degradation products (Accu-Dx) test in bladder cancer patients. Eur Urol 2001; 39:287-91.
29. Zaher A, Sheridan T. Tumor markers in the detection of recurrent transitional cell carcinoma of the bladder: a brief review. Acta Cytol 2001; 45:575-81.
30. Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001; 285:324-8.
31. Konety BR, Nguyen TS, Brenes G, et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol 2000; 164:634-9.
32. Vriesema JL, Atsma F, Kiemeney LA, et al. Diagnostic efficacy of the Immunocyt test to detect superficial bladder cancer recurrence. Urology 2001; 58:367-71.
33. Saad A, Hanbury DC, McNicholas TA, et al. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002; 89:369-73.
34. Lokeshwar VB, Schroeder GL, Selzer MG, et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-stat tests. Cancer 2002; 95:61-72.
35. Burchardt M, Burchardt T, Shabsigh A, et al. Current concepts in biomarker technology for bladder cancers. Clin Chem 2000; 46:595-605.
36. Carrion R, Seigne J. Surgical management of bladder carcinoma. Cancer Control 2002; 9:284-92.
37. Vallancien G, Abou El Fettouh H, Cathelineau X, et al. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 2002; 168:2413-17.
38. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64:2448-58.
39. Logothetis CJ, Dexeus FH, Chong C, et al. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J Urol 1989; 141:33-7.
40. Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145:459-64.
41. Yan Y, Andriole GL, Humphrey PA, Kibel AS. Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Cancer 2002; 95:1239-46.
42. Fukushima S, Ozono S, Hinotsu S, et al. Treated natural history of superficial bladder cancer. Jpn J Clin Oncol 2001; 31:536-40.
43. Althausen AF, Prout GR Jr, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976; 116:575-80.
44. de Vere White RW, Stapp E. Predicting prognosis in patients with superficial bladder cancer. Oncology (Williston Park) 1998; 12:1717-23.
45. Narayana AS, Loening SA, Slymen DJ, Culp DA. Bladder cancer: factors affecting survival. J Urol 1983; 130:56-60.
46. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983; 130:1083-6.
47. Sternberg CN. A critical review of the management of bladder cancer. Crit Rev Oncol Hematol 1999; 31:193-207.